Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019;30(Suppl_8):viii16-viii22.

Ouseph MM, Taber A, Khurshid H, Madison R, Aswad BI, Resnick MB, et al. TKI-resistant -rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations. Lung Cancer (Auckl). 2019;10:81-86.

Cho KR, Cooper K, Croce S, Djordevic B, Herrington S, Howitt B, et al. International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. Int J Gynecol Pathol. 2019;38 Suppl 1:S114-S122.

Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019;133(11):1201-1204.

Sfeir MM, Hayden JA, Fauntleroy KA, Mazur C, Johnson JK, Simner PJ, et al. EDTA-Modified Carbapenem Inactivation Method: a Phenotypic Method for Detecting Metallo-β-Lactamase-Producing . J Clin Microbiol. 2019;57(5).

Kodiyanplakkal RP, Laplante JM, Westblade LF, Van Besien K, Salvatore M, St George K. Detection and Characterization of Influenza B Virus With Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient. Open Forum Infect Dis. 2019;6(12):ofz493.

Giunchi F, Fiorentino M, Loda M. The Metabolic Landscape of Prostate Cancer. Eur Urol Oncol. 2019;2(1):28-36.

Chidambaram S, Pannullo SC, Roytman M, Pisapia DJ, Liechty B, Magge RS, et al. Dynamic contrast-enhanced magnetic resonance imaging perfusion characteristics in meningiomas treated with resection and adjuvant radiosurgery. Neurosurg Focus. 2019;46(6):E10.

Tierney JF, Vogle A, Poirier J, Min IM, Finnerty B, Zarnegar R, et al. Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: An exploratory study. Surgery. 2019;165(1):196-201.

Chang R, Tosi U, Voronina J, Adeuyan O, Wu LY, Schweitzer ME, et al. Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy. Neurooncol Adv. 2019;1(1):vdz004.